首页> 外文期刊>Perfusion >Monitoring of low molecular weight heparin anticoagulation during haemodialysis with a Sonoclot Analyzer.
【24h】

Monitoring of low molecular weight heparin anticoagulation during haemodialysis with a Sonoclot Analyzer.

机译:使用Sonoclot分析仪监测血液透析期间的低分子量肝素抗凝作用。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVES: Sonoclot was used in this study to monitor low molecular weight heparin (LMWH) during haemodialysis. MATERIAL AND METHODS: Two different intravenous doses (standard / half-dose) of dalteparin were studied in eight patients. Blood was sampled for coagulation analyses with Sonoclot, thrombin-antithrombin (TAT) and anti-Xa. A visual fibrin deposition score (VFS) in the venous drip chamber was also evaluated. RESULTS: All patients completed their dialysis. There was a progressive increase in TAT levels, which correlated to the dalteparin dose. Significant differences (p<0.05) were found for TAT, VFS and Sonoclot celite-activated clotting time (SonACT) between the different LMWH dosages. TAT and Sonoclot correlated to each other, but not to the VFS. SonACT was significantly increased at two hours, with the high dalteparin dose compared to the lower dose. CONCLUSION: Both Sonoclot and TAT failed to predict the VFS. No patient had any clinical clotting events and all dialyses were completed successfully.
机译:目的:在血液透析过程中使用Sonoclot监测低分子量肝素(LMWH)。材料与方法:在八位患者中研究了两种不同静脉注射剂量(标准剂量/半剂量)的达肝素。对血样进行采样,以使用Sonoclot,凝血酶-抗凝血酶(TAT)和抗Xa进行凝血分析。还评估了静脉滴注室内的视觉纤维蛋白沉积评分(VFS)。结果:所有患者均完成了透析。 TAT水平逐渐升高,这与达肝素剂量有关。发现不同LMWH剂量之间的TAT,VFS和Sonoclot硅藻土活化凝血时间(SonACT)有显着差异(p <0.05)。 TAT和Sonoclot相互关联,但与VFS不相关。与低剂量相比,高剂量的达肝素在两个小时内SonACT显着增加。结论:Sonoclot和TAT均无法预测VFS。没有患者发生任何临床凝血事件,并且所有透析均成功完成。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号